Effects of ADAM10 upregulation on progression, migration, and prognosis of nasopharyngeal carcinoma

• DOI: 10.1111/cas.12800
• Publication Date: 2015-08-27T08:02:37Z
• Authors: Bo You; Ying Shan; Si Shi; Xingyu Li; Yiwen You
• Keywords: Male; 0301 basic medicine; Nasopharyngeal Carcinoma; Blotting, Western; Carcinoma; Fluorescent Antibody Technique; Membrane Proteins; Nasopharyngeal Neoplasms; Original Articles; Kaplan-Meier Estimate; Middle Aged; Prognosis; Immunohistochemistry; 3. Good health; ADAM Proteins; ADAM10 Protein; 03 medical and health sciences; Cell Movement; Biomarkers, Tumor; Disease Progression; Humans; Female; Amyloid Precursor Protein Secretases; Aged

A disintegrin and metalloprotease 10 (ADAM10) is a typical member of the ADAMs family, which has been reported to be upregulated in various types of cancers and contribute to cancer progression and metastasis. However, little is known about the role of ADAM10 in nasopharyngeal carcinoma (NPC). The purpose of this study is to explore ADAM10 expression status and its biological functions in NPC. We first examined the expression of ADAM10 in NPC tissues and cell lines by immunohistochemistry, Western blotting, PCR, and immunofluorescence analysis. We observed that ADAM10 was significantly elevated in NPC and its expression level was correlated with T classification (P = 0.044), distant metastasis (P = 0.016), TNM clinical stage (P = 0.013), and proliferation marker Ki‐67 expression (P = 0.001). Patients with NPC with high expression of ADAM10 had shorter overall survival rates. In addition, knockdown of ADAM10 by RNAi was found to inhibit the CNE‐2 cell proliferation and migration. Our findings hinted that overexpression of ADAM10 promotes the progression and migration of NPC, which makes it a potential therapeutic target for the treatment of tumor metastases in NPC.